Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Exclusion Criteria

• •Subjects who meet any of the following criteria will be excluded from participation in this study:
• •1. Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)
• •2. History of another primary malignancy that has not been in remission for at least 2 years.
• •3. Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
• •4. Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection at the time of screening
• •5. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or JWCAR029 administration
• •6. Presence of acute or chronic graft-versus-host disease (GVHD)
• •7. History of cardiovascular disease
• •8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
• •9. Pregnant or nursing women.
• •10. Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JWCAR029 treatment in this protocol for subjects receiving retreatment